Identification of a serotonin/glutamate receptor complex implicated in psychosis
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
The psychosis associated with schizophrenia is characterized by alterations in sensory processing and perception. Some antipsychotic drugs were identified by their high affinity for serotonin 5-HT2A receptors (2AR). Drugs that interact with metabotropic glutamate receptors (mGluR) also have potential for the treatment of schizophrenia. The effects of hallucinogenic drugs, such as psilocybin and lysergic acid diethylamide, require the 2AR and resemble some of the core symptoms of schizophrenia. Here we show that the mGluR2 interacts through specific transmembrane helix domains with the 2AR, a member of an unrelated G-protein-coupled receptor family, to form functional complexes in brain cortex. The 2AR-mGluR2 complex triggers unique cellular responses when targeted by hallucinogenic drugs, and activation of mGluR2 abolishes hallucinogen-specific signalling and behavioural responses. In post-mortem human brain from untreated schizophrenic subjects, the 2AR is upregulated and the mGluR2 is downregulated, a pattern that could predispose to psychosis. These regulatory changes indicate that the 2AR-mGluR2 complex may be involved in the altered cortical processes of schizophrenia, and this complex is therefore a promising new target for the treatment of psychosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, the 5HT2A receptor forms a functional heterodimer with the mGluR2 receptor, which evokes allosteric effects on serotonin agonist binding [34];”
From Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans. (2021) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“this interaction reduces the hallucinogen-specific Gi/o protein signaling and behavior and may account for the lack of hallucinogenic action of 2-bromo-LSD (5) noted above.”
From Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans. (2021) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Temporal pattern encoding relieves the cellular information bottleneck, where many stimuli must signal through few intracellular pathways to generate diverse and specific cellular responses (30 -32) but complicates the relationship between synthetic target modulators and their cellular and clinical effects.”
From Cytokine Response Is Determined by Duration of Receptor and Signal Transducers and Activators of Transcription 3 (STAT3) Activation (2013) · cites this paper as [31]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Several recent studies of drugs acting at cell surface receptor targets show that the activation mechanisms responsible for their cellular and systemic effects are more complex than accounted for by their classical pharmacological profiles (30 -32).”
From Cytokine Response Is Determined by Duration of Receptor and Signal Transducers and Activators of Transcription 3 (STAT3) Activation (2013) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Basic local alignment search tool
Altschul, S. F., Gish, W., Miller, W., Myers, E. W., & Lipman, D. J. (1990) · Journal of Molecular Biology · doi:10.1006/jmbi.1990.9999 · Cited by 98,669
Thompson, J. D., Higgins, D. G., & Gibson, T. J. (1994) · Nucleic Acids Research · doi:10.1093/nar/22.22.4673 · Cited by 64,617
Comparative Protein Modelling by Satisfaction of Spatial Restraints
Šali, A., & Blundell, T. L. (1993) · Journal of Molecular Biology · doi:10.1006/jmbi.1993.1626 · Cited by 12,977
Crystal Structure of Rhodopsin: A G Protein-Coupled Receptor
Palczewski, K., Kumasaka, T., Hori, T., Behnke, C. A., Motoshima, H., Fox, B. A., Trong, I. L., Teller, D. C., Okada, T., Stenkamp, R. E., et al. (2000) · Science · doi:10.1126/science.289.5480.739 · Cited by 5,637
High-Resolution Crystal Structure of an Engineered Human β 2 -Adrenergic G Protein–Coupled Receptor
Cherezov, V., Rosenbaum, D. M., Hanson, M. A., Rasmussen, S. G. F., Thian, F. S., Kobilka, T. S., Choi, H.-J., Kuhn, P., Weis, W. I., Kobilka, B. K., et al. (2007) · Science · doi:10.1126/science.1150577 · Cited by 3,264
Patil, S. T., Zhang, L., Martenyi, F., Lowe, S. L., Jackson, K. A., Andreev, B. V., Avedisova, A. S., Bardenstein, L. M., Gurovich, I. Y., Morozova, M. A., et al. (2007) · Nature Medicine · doi:10.1038/nm1632 · Cited by 1,040
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., & Hell, D. (1998) · NeuroReport · doi:10.1097/00001756-199812010-00024 · Cited by 1,018
Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988
González-Maeso, J., Weisstaub, N. V., Zhou, M., Chan, P., Ivic, L., Ang, R., Lira, A., Bradley-Moore, M., Ge, Y., Zhou, Q., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.008 · Cited by 925
Self-citation
Cited by
Items 301–400 of 835
An association study of DRD2 gene polymorphisms with schizophrenia in a Chinese Han population
Fan, H., Zhang, F., Xu, Y. J., Huang, X., Sun, G., Song, Y., Long, H., & Liu, P. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.11.017 · Cited by 53
Millan, M. J., & Brocco, M. (2008) · Therapies · doi:10.2515/therapie:2008041 · Cited by 47
Filizola, M. (2009) · Life Sciences · doi:10.1016/j.lfs.2009.05.004 · Cited by 48
“2004), serotonin 5-HT2A-metabotropic glutamate receptor 2 heterodimer (Gonzalez-Maeso et al. 2008), and corticotropin releasing hormone-VT2 arginine vasotocin receptor heterodimer (Mikhailova et al.”
BackgroundMethodInfluentialSelf-citationG-protein-coupled receptor type A heteromers as an emerging therapeutic target
Guidolin, D., Agnati, L. F., Marcoli, M., Borroto‐Escuela, D. O., & Fuxé, K. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.981155 · Cited by 45
“The 5HT2A receptor was also involved in other relevant RRIs taking place in the mGlu2--HT2A heteroreceptor complex [152], which was proposed to be a promising new target for the treatment of psychosis.”
BackgroundMolinaro, G., Traficante, A., Riozzi, B., Menna, L. D., Curto, M., Pallottino, S., Nicoletti, F., Bruno, V., & Battaglia, G. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.056580 · Cited by 46
Catalysts for change: the cellular neurobiology of psychedelics
Banks, M. I., Zahid, Z., Jones, N. T., Sultan, Z. W., & Wenthur, C. J. (2021) · Molecular Biology of the Cell · doi:10.1091/mbc.e20-05-0340 · Cited by 37
“Further, several studies indicate that 5-HT2AR and mGluR2 form heterodimeric complexes, integrating glutamatergic and serotonergic signaling and modulating subsequent G-protein coupling and downstream effects (Zhai et al., 2003; Gonzalez-Maeso et al., 2008; Moreno et al., 2016).”
BackgroundInfluentialKawasaki, T., Ago, Y., Yano, K., Araki, R., Washida, Y., Onoe, H., Chaki, S., Nakazato, A., Hashimoto, H., Baba, A., et al. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.10.009 · Cited by 46
Negative cooperativity in H2 relaxin binding to a dimeric relaxin family peptide receptor 1
Svendsen, A. M., Zalesko, A., Kønig, J., Vrecl, M., Heding, A., Kristensen, J. B., Wade, J. D., Bathgate, R. A. D., MEYTS, P. D., & Nøhr, J. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.07.014 · Cited by 45
“The 13 recent implication of heterodimers between serotonin and glutamate receptors in schizophrenia 14 underlines the potential importance of this mechanism (González-Maeso et al., 2008).”
BackgroundBiomarker investigations related to pathophysiological pathways in schizophrenia and psychosis
Chana, G., Bousman, C., Money, T., Gibbons, A. S., Gillett, P., Dean, B., & Everall, I. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00095 · Cited by 45
“(Gonzalez-Maeso et al., 2008).”
BackgroundAghajanian, G. K. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1484-9 · Cited by 38
“However, a recent study reported that 5-HT2A and mGluR2 receptors form a macromolecular complex, allowing allosteric interactions to occur between the two receptors in the same cells (Gonzalez-Maeso et al. 2008).”
BackgroundGlutamate heteroreceptor complexes in the brain
Borroto‐Escuela, D. O., Tarakanov, A. O., Brito, I., & Fuxé, K. (2018) · Pharmacological Reports · doi:10.1016/j.pharep.2018.04.002 · Cited by 47
Elfving, B., Müller, H. K., Oliveras, I., Østerbøg, T. B., Río-Álamos, C., Sánchez-González, A., Tobeña, A., Fernández‐Teruel, A., & Aznar, S. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.109669 · Cited by 45
Frouni, I., Hamadjida, A., Kwan, C., Bédard, D., Nafade, V., Gaudette, F., Nuara, S. G., Gourdon, J. C., Beaudry, F., & Huot, P. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107725 · Cited by 47
Interclass GPCR heteromerization affects localization and trafficking
Toneatti, R., Shin, J. M., Shah, U. H., Mayer, C. R., Saunders, J. M., Fribourg, M., Arsenovic, P. T., Janssen, W. G. M., Sealfon, S. C., López‐Giménez, J. F., et al. (2020) · Science Signaling · doi:10.1126/scisignal.aaw3122 · Cited by 44
Self-citationMolecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans.
Cumming, P., Scheidegger, M., Dornbierer, D., Palner, M., Quednow, B. B., & Martin-Soelch, C. (2021) · Molecules · doi:10.3390/molecules26092451 · Cited by 43
“Furthermore, the 5HT2A receptor forms a functional heterodimer with the mGluR2 receptor, which evokes allosteric effects on serotonin agonist binding [34]; this interaction reduces the hallucinogen-specific Gi/o protein signaling and behavior and may account for the lack of hallucinogenic action of 2-bromo-LSD (5) not…”
BackgroundDopamine D2 heteroreceptor complexes and their receptor–receptor interactions in ventral striatum
Fuxé, K., Borroto‐Escuela, D. O., Tarakanov, A. O., Romero‐Fernandez, W., Ferraro, L., Tanganelli, S., Pérez‐Alea, M., Palma, M. D., & Agnati, L. F. (2014) · Progress in brain research · doi:10.1016/b978-0-444-63425-2.00005-2 · Cited by 51
Psychoactive Substances and Paranormal Phenomena: A Comprehensive Review
Luke, D. P. (2012) · International Journal of Transpersonal Studies · doi:10.24972/ijts.2012.31.1.97 · Cited by 42
“…responsible for such similar experiences with these divergent molecules (Vollenweider, 2004); this serotonin/ glutamate receptor-complex model of drug action is receiving high-profile attention again for psychedelics as a possible comparative model of psychosis (e.g., González-Maeso et al., 2008).”
BackgroundExcitements and Challenges in GPCR Oligomerization: Molecular Insight from FRET
Chakraborty, H., & Chattopadhyay, A. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn500231d · Cited by 45
The ZnR/GPR39 Interacts With the CaSR to Enhance Signaling in Prostate and Salivary Epithelia
Asraf, H., Salomon, S., Nevo, A., Sekler, I., Mayer, D., & Hershfinkel, M. (2013) · Journal of Cellular Physiology · doi:10.1002/jcp.24514 · Cited by 42
Stachowicz, K., Kłodzińska, A., Palucha-Poniewiera, A., Schann, S., Neuville, P., & Pilc, A. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.06.005 · Cited by 39
“, 2002) and recently, a complex of 5-HT2/mGlu2 receptors has been identified and implicated in psychosis (González-Maeso et al., 2008), nothing is known about interactions between mGlu and 5-HT1A receptors.”
BackgroundHoriguchi, M., Hannaway, K. E., Adelekun, A. E., Huang, M., Jayathilake, K., & Meltzer, H. Y. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.09.030 · Cited by 43
Oligomerization of GPCRs involved in endocrine regulation
Kleinau, G., Müller, A., & Biebermann, H. (2016) · Journal of Molecular Endocrinology · doi:10.1530/jme-16-0049 · Cited by 43
Provasi, D., Johnston, J. M., & Filizola, M. (2010) · Biochemistry · doi:10.1021/bi100686t · Cited by 41
“The ability of GPCR dimers and oligomers to associate and dissociate rapidly suggests relatively small standard free energy differences between dimeric and monomeric GPCRs compared to those of protein complexes stabilized by multiple specific bonds.”
BackgroundInfluentialSelf-citationPehrson, A. L., & Moghaddam, B. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1914-8 · Cited by 41
Richtand, N. M., Ahlbrand, R., Horn, P., Stanford, K., Bronson, S. L., & McNamara, R. K. (2011) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2011.02.007 · Cited by 38
“Functional connections between serotonin 5-HT2A receptors and glutamate mGluR2 receptors (Gonzalez-Maeso et al., 2008) provide one plausible mechanism linking 5-HT2A receptor effects with glutamate system interactions potentially involved in the developmental pathology of dopamine system abnormalities (Carlsson et al.”
BackgroundQuednow, B. B., Geyer, M. A., & Halberstadt, A. L. (2010) · Handbook of Behavioral Neuroscience · doi:10.1016/s1569-7339(10)70102-8 · Cited by 33
The Effects of Psychedelics on Neuronal Physiology
Hatzipantelis, C. J., & Olson, D. E. (2023) · Annual Review of Physiology · doi:10.1146/annurev-physiol-042022-020923 · Cited by 44
“The 5-HT 2A R is known to form complexes with a variety of GPCRs that may alter its function, including metabotropic glutamate, dopamine, cannabinoid, and serotonin receptors (46–49).”
Bruno, A., Costantino, G., de Fabritiis, G., Pastor, M., & Selent, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042023 · Cited by 37
“The class C Metabotropic glutamate receptor type 2 (mGluR2) has received attention as a potential drug target [11–15] and has been recently described to be involved in the heteromerization with the class A 5-HT2A serotonin receptors [11,14,15].”
BackgroundMoore, H. M. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq106 · Cited by 43
“mechanisms that may contribute significantly to psychopathology in schizophrenia.(6,12,15,16) However, the drugs discovered with this approach are necessarily constrained by the pharmacology of preexisting drugs.”
BackgroundRepressive Epigenetic Changes at the mGlu2 Promoter in Frontal Cortex of 5-HT2A Knockout Mice
Kurita, M., Moreno, J. L., Holloway, T. D., Kozlenkov, A., Mocci, G., García‐Bea, A., Hanks, J. B., Neve, R. L., Nestler, E. J., Russo, S. J., et al. (2013) · Molecular Pharmacology · doi:10.1124/mol.112.084582 · Cited by 43
“It has been recently shown that chronic treatment with the atypical antipsychotics clozapine or risperidone, but not with the typical antipsychotic haloperidol, decreases the density of 5- HT2A receptor in mouse frontal cortex (Gonzalez-Maeso et al., 2008; Kurita et al., 2012; Moreno et al., 2013b).”
BackgroundMethodInfluentialSelf-citationBorroto‐Escuela, D. O., & Fuxé, K. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00230 · Cited by 43
Fuxe, K., Marcellino, D., Woods, A. S., Giuseppina, L., Antonelli, T., Ferraro, L., Tanganelli, S., & Agnati, L. F. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-008-0174-9 · Cited by 42
“This will reduce the hallucinogenic-specific Gi/o signaling and behavior over the 5-HT2A receptor with a reduction of primary disturbances in cortical sensory processing (Gonzalez-Maeso et al. 2008).”
InfluentialKo, C., & Liu, Y. (2015) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2015.08.003 · Cited by 41
Zoenen, M., Urizar, E., Swillens, S., Vassart, G., & Costagliola, S. (2012) · Nature Communications · doi:10.1038/ncomms1991 · Cited by 43
Understanding GPCR dimerization
Faron‐Górecka, A., Szlachta, M., Kolasa, M., Solich, J., Górecki, A., Kuśmider, M., Żurawek, D., & Dziedzicka‐Wasylewska, M. (2018) · Methods in cell biology · doi:10.1016/bs.mcb.2018.08.005 · Cited by 45
Classification and Signaling Characteristics of 5-HT Receptors
Bockaert, J., Claeysen, S., Dumuis, A., & Marin, P. (2010) · Handbook of behavioral neuroscience · doi:10.1016/s1569-7339(10)70073-4 · Cited by 47
“A) In somato-sensoriel cortex, (Gonzalez-Maeso et al., 2008) showed a hetero- dimerization between mGluR2 and 5-HT2A receptors.”
BackgroundInfluentialMcOmish, C. E., Pavey, G., Gibbons, A. S., Hopper, S., Udawela, M., Scarr, E., & Dean, B. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.10.004 · Cited by 40
Williams, A. A., Ingram, W. M., Levine, S., Resnik, J., Kamel, C. M., Lish, J. R., Elizalde, D. I., Janowski, S. A., Shoker, J., Kozlenkov, A., et al. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.81 · Cited by 41
“…(DuPont-NEN, Boston, MA) binding (0.0625–10 nM; 10 concentrations) to 5HT2AR was measured at equilibrium in 500 ml aliquots (50 mM Tris-HCl; pH 7.4) of membrane preparations (10–57 mg protein per tube), which were incubated at 37 1C for 60 min as described previously (Gonzalez-Maeso et al, 2008).”
MethodSelf-citationThe promiscuous mGlu5 receptor – a range of partners for therapeutic possibilities?
Bird, M. K., & Lawrence, A. J. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.09.008 · Cited by 39
Fomsgaard, L., Moreno, J. L., Revenga, M. D. L. F., Brudek, T., Adamsen, D., Río-Álamos, C., Saunders, J. M., Klein, A. B., Oliveras, I., Cañete, T., et al. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0457-y · Cited by 40
“Pharmacological activation of the mGlu2/3 receptor complex suppresses the intracellular and behavioral effects of the hallucinogenic 5-HT2A receptor agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) [29].”
InfluentialSelf-citationWischhof, L., Irrsack, E., Dietz, F., & Koch, M. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.05.029 · Cited by 45
Wischhof, L., & Koch, M. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2441-y · Cited by 38
“2000) and have been found to form functional complexes via specific transmembrane domains on cortical pyramidal cells (Gonzalez-Maeso et al. 2008).”
BackgroundInfluentialFraley, M. E. (2009) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543770903045009 · Cited by 38
“The identification of compounds possessing this unique blend of dual activity may represent a strategy related to the finding that mGluR2 forms a functional complex with 5-HT2A in the cerebral cortex through association of its transmembrane helices IV and V [58].”
BackgroundSantini, M. A., Ratner, C., Aznar, S., Klein, A. B., Knudsen, G. M., & Mikkelsen, J. D. (2013) · Journal of Neuroscience Research · doi:10.1002/jnr.23198 · Cited by 38
“This is particularly relevant in imaging and post-mortem binding studies in which changes in cortical 5-HT2AR binding may not be correlated with functional impact (Gonzalez-Maeso et al., 2008; Rasmussen et al., 2010; Ebdrup et al., 2011).”
BackgroundCross-signaling in metabotropic glutamate 2 and serotonin 2A receptor heteromers in mammalian cells
Baki, L., Fribourg, M., Younkin, J., Eltit, J. M., Moreno, J. L., Park, G., Vysotskaya, Z. V., Narahari, A. K., Sealfon, S. C., González‐Maeso, J., et al. (2016) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-015-1780-7 · Cited by 43
“N-terminally c-Myc-tagged wild-type human 5-HT2A (Myc2AR) and N-terminally HA-tagged human mGlu2R (HAmGlu2R) have been previously described [13].”
Self-citationA neuroscientific model of near-death experiences
Martial, C., Fritz, P., Gosseries, O., Bonhomme, V. L., Kondziella, D., Nelson, K. R., & Lejeune, N. (2025) · Nature Reviews Neurology · doi:10.1038/s41582-025-01072-z · Cited by 40
Pottie, E., & Stove, C. P. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15570 · Cited by 37
Wierońska, J. M., Acher, F., Sławińska, A., Gruca, P., Łasoń, M., Papp, M., & Pilc, A. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3005-0 · Cited by 38
Biological Significance of GPCR Heteromerization in the Neuro-Endocrine System
Kamal, M. T., & Jockers, R. (2011) · Frontiers in Endocrinology · doi:10.3389/fendo.2011.00002 · Cited by 42
Interactive effects of mGlu5 and 5-HT2A receptors on locomotor activity in mice
Halberstadt, A. L., Lehmann-Masten, V. D., Geyer, M. A., & Powell, S. B. (2011) · Psychopharmacology · doi:10.1007/s00213-010-2115-1 · Cited by 33
“It was recently suggested that mGlu2 and 5-HT2A receptors directly form heterocomplexes in mouse frontal cortex (Gonzalez-Maeso et al. 2008); hence, a direct interaction between the two receptors may explain the regulation of 5-HT2A responses by mGlu2.”
Direct Interaction of GABABReceptors with M2Muscarinic Receptors Enhances Muscarinic Signaling
Boyer, S. B., Clancy, S. M., Terunuma, M., Revilla-Sanchez, R., Thomas, S. M., Moss, S. J., & Slesinger, P. A. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.4103-09.2009 · Cited by 36
“Interestingly, this association correlates with a change in signaling found in patients with schizophrenia (González-Maeso et al., 2008).”
BackgroundInfluentialWierońska, J. M., Sławińska, A., Stachowicz, K., Łasoń, M., Gruca, P., Papp, M., & Pilc, A. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.08.007 · Cited by 36
GPCR interaction as a possible way for allosteric control between receptors
Pin, J., Kniazeff, J., Prézeau, L., Liu, J.-F., & Rondard, P. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.02.019 · Cited by 39
Marin, P., Bécamel, C., Chaumont‐Dubel, S., Vandermoere, F., Bockaert, J., & Claeysen, S. (2020) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-444-64125-0.00005-0 · Cited by 46
Wulff, A. B., Nichols, C. D., & Thompson, S. M. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109504 · Cited by 42
Kanagarajadurai, K., Malini, M., Bhattacharya, A., Panicker, M. M., & Sowdhamini, R. (2009) · Molecular BioSystems · doi:10.1039/b906391a · Cited by 36
Murat, S., Bigot, M., Chapron, J., König, G. M., Kostenis, E., Battaglia, G., Nicoletti, F., Bourinet, E., Bockaert, J., Marin, P., et al. (2018) · Molecular Psychiatry · doi:10.1038/s41380-018-0069-6 · Cited by 39
“Several studies also reported changes in 5-HT2A and mGlu2 receptor densities in patients with schizophrenia, which might contribute to the pathogenicity of the disease [9, 12, 46].”
BackgroundInfluentialBeyond dopamine: Novel strategies for schizophrenia treatment
Dudzik, P., Lustyk, K., & Pytka, K. (2024) · Medicinal Research Reviews · doi:10.1002/med.22042 · Cited by 36
“121 This coincidence suggests that combined signaling through those receptors is responsible for the regulation of the sensory gating functions, which are severely impaired in schizophrenia patients.”
Liu, H., Tian, Y., Ji, B., Lu, H., Xin, Q., Jiang, Y., Ding, L., Zhang, J., Chen, J., & Bai, B. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.07.009 · Cited by 38
Attenuation of Oxytocin and Serotonin 2A Receptor Signaling through Novel Heteroreceptor Formation
Chruścicka, B., Fitzsimons, S. E. W., Borroto‐Escuela, D. O., Druelle, C. M., Stamou, P., Nally, K., Dinan, T. G., Cryan, J. F., Fuxé, K., & Schellekens, H. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00665 · Cited by 35
Saunders, J. M., Moreno, J. L., Ibi, D., Sikaroodi, M., Kang, D. J., Muñoz-Moreno, R., Dalmet, S. S., García‐Sastre, A., Gillevet, P. M., Dozmorov, M. G., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-61635-6 · Cited by 37
Self-citationSchizophrenia therapy: beyond atypical antipsychotics
Snyder, E. M., & Murphy, M. R. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2571 · Cited by 35
Nicoletti, F., Menna, L. D., Iacovelli, L., Orlando, R., Zuena, A. R., Conn, P. J., Dogra, S., & Joffe, M. E. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109569 · Cited by 36
Hadamitzky, M., Feja, M., Becker, T., & Koch, M. (2009) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e3283305e11 · Cited by 35
“When targeted by hallucinogenic drugs, such as lysergic acid diethylamide and psilocybin, this 5-HT2A–mGluR2 complex triggers unique cellular responses (González-Maeso et al., 2008).”
BackgroundAgnati, L. F., Guidolin, D., Vilardaga, J., Ciruela, F., & Fuxé, K. (2010) · Journal of Receptors and Signal Transduction · doi:10.3109/10799891003786226 · Cited by 39
Sid‐Otmane, L., Hamadjida, A., Nuara, S. G., Bédard, D., Gaudette, F., Gourdon, J. C., Michaud, V., Beaudry, F., Panisset, M., & Huot, P. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.172957 · Cited by 34
A Comprehensive Review of the Current Status of the Cellular Neurobiology of Psychedelics
Banushi, B., & Polito, V. (2023) · Biology · doi:10.3390/biology12111380 · Cited by 37
Purkayastha, S., Ford, J. R., Kanjilal, B., Diallo, S., Inigo, J. D. R., Neuwirth, L. S., Idrissi, A. E., Ahmed, Z., Wieraszko, A., Azmitia, E. C., et al. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07565.x · Cited by 36
“In subjects with schizophrenia, this complex is disrupted by suppressed expression of mGluR2, thus predisposing them to psychosis (Gonzalez-Maeso et al. 2008).”
BackgroundRossi, G. N., Guerra, L. T. L., Baker, G. B., Dursun, S. M., Bouso, J. C., Hallak, J. E. C., & SANTOS, R. G. D. (2022) · Biomolecules · doi:10.3390/biom12111618 · Cited by 40
Aira, Z., Buesa, I., del Caño, G. G., Bilbao, J., Doñate-Oliver, F., Zimmermann, M., & Azkue, J. J. (2013) · Pain · doi:10.1016/j.pain.2013.06.009 · Cited by 33
“In addition, the 5-HT2 receptor and mGluR2 can form complexes that exhibit unique responses to drugs and have been implicated in schizophrenia [26,53].”
BackgroundCornett, L. E., Kang, S. W., & Kuenzel, W. J. (2013) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2013.02.032 · Cited by 33
The role of metabotropic glutamate receptors in addiction: Evidence from preclinical models
Duncan, J. R., & Lawrence, A. J. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.03.015 · Cited by 36
Metabotropic Glutamate Receptors: Potential Drug Targets for Psychiatric Disorders
Yasuhara, A., & Chaki, S. (2010) · The Open Medicinal Chemistry Journal · doi:10.2174/1874104501004020020 · Cited by 34
“It was also recently shown that the 5-HT2A and mGlu2 receptors formed a heterodimeric complex [38].”
BackgroundBenzekhroufa, K., Liu, B.-H., Teschemacher, A. G., & Kasparov, S. (2009) · Gene Therapy · doi:10.1038/gt.2009.7 · Cited by 34
Esnal, A., Sánchez-González, A., Río-Álamos, C., Oliveras, I., Cañete, T., Blázquez, G., Tobeña, A., & Fernández‐Teruel, A. (2016) · Physiology & Behavior · doi:10.1016/j.physbeh.2016.05.020 · Cited by 34
Biophysical validation of serotonin 5-HT2A and 5-HT2C receptor interaction
Felsing, D. E., Anastasio, N. C., Miszkiel, J., Gilbertson, S. R., Allen, J., & Cunningham, K. A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0203137 · Cited by 33
Dean, B. (2012) · Current Topics in Medicinal Chemistry · doi:10.2174/156802612805289935 · Cited by 34
“However, in studies using membrane based assays, rather than autoradiography, levels of 5HT2AR have been reported as either unchanged [126] or increased [127] in schizophrenia.”
BackgroundThe evolution of N, N-Dimethyltryptamine: from metabolic pathways to brain connectivity
Gupta, S., Bhatnagar, R. K., Gupta, D., Maharaj Kumari, K., & Chopra, A. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06777-z · Cited by 32
“Hyperconnectivity in the amygdala, hippocampus, and sensory cortices results in vivid hallucination, altered perception, and time distortion (González-Maeso et al. 2008; Delille et al. 2012; Carbonaro et al. 2015).”
Strategies and considerations of G-protein-coupled receptor photopharmacology
Berizzi, A. E., & Goudet, C. (2020) · Advances in pharmacology · doi:10.1016/bs.apha.2019.12.001 · Cited by 37
Ibi, D., Nakasai, G., Koide, N., Sawahata, M., Kohno, T., Takaba, R., Nagai, T., Hattori, M., Nabeshima, T., Yamada, K., et al. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00285 · Cited by 34
“Some characteristic neuropathological features of schizophrenia are also seen in the offspring of mothers treated with polyI:C during pregnancy (Gonzalez-Maeso et al., 2008; Jaaro-Peled et al., 2010).”
BackgroundNovel and atypical pathways for serotonin signaling
Bockaert, J., Bécamel, C., Chaumont‐Dubel, S., Claeysen, S., Vandermoere, F., & Marin, P. (2021) · Faculty Reviews · doi:10.12703/r/10-52 · Cited by 32
Drug‐resistant epilepsy: Drug target hypothesis and beyond the receptors
Fonseca‐Barriendos, D., Frías‐Soria, C. L., Pérez‐Pérez, D., Gómez‐López, R., Escuela, D. O. B., & Rocha, L. (2021) · Epilepsia Open · doi:10.1002/epi4.12539 · Cited by 36
The crosstalk between 5-HT2AR and mGluR2 in schizophrenia
Saha, S., & González‐Maeso, J. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109489 · Cited by 33
Self-citationGPCR dimerization in brainstem nuclei contributes to the development of hypertension
Sun, G., Ho, W., Chen, B., Cheng, P., Cheng, W., Hsu, M., Yeh, T., Hsiao, M., Lu, P., & Tseng, C. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13074 · Cited by 36
“, 2006); and psychosis might be caused by inhibiting 5-HT2A agonist-induced signalling via 5-HT2A receptor/mGlu receptor heterodimers in cortical pyramidal neurons (Gonzalez-Maeso et al., 2008).”
Ster, J., Mateos, J. M., Grewe, B. F., Coiret, G., Corti, C., Corsi, M., Helmchen, F., & Gerber, U. R. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1100548108 · Cited by 35
“In patients with schizophrenia, there is down-regulation of mGluR2 (22) and alterations in mGluR3 (23).”
BackgroundKandaswamy, R., McQuillin, A., Sharp, S. I., Fiorentino, A., Anjorin, A., Blizard, R., Curtis, D., & Gurling, H. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.38 · Cited by 35
Negative Allosteric Modulators of mGlu7 Receptor as Putative Antipsychotic Drugs
Cieślik, P., Woźniak, M., Kaczorowska, K., Brański, P., Burnat, G., Chocyk, A., Bobula, B., Gruca, P., Litwa, E., Pałucha-Poniewiera, A., et al. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00316 · Cited by 33
Klotz, L., Wendler, O., Frischknecht, R., Shigemoto, R., Schulze, H., & Enz, R. (2019) · The FASEB Journal · doi:10.1096/fj.201901543r · Cited by 34
“using 3 aa present within the receptors transmembrane domain 4 (57, 58).”
MethodBenzekhroufa, K., Liu, B., Tang, F., Teschemacher, A. G., & Kasparov, S. (2009) · BMC Biotechnology · doi:10.1186/1472-6750-9-23 · Cited by 34
“Background Animal and human studies have associated the serotonergic (5 HTergic) system with diseases such as depression and anxiety [1-3], or schizophrenia [4,5].”
BackgroundPathophysiology and Animal Models of Schizophrenia
Dawe, G. S., Hwang, E. H. J., & Tan, C. H. (2009) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.v38n5p425 · Cited by 42
Gerbier, R., Ndiaye‐Lobry, D., de Morentin, P. B. M., Cecon, E., Heisler, L. K., Delagrange, P., Gbahou, F., & Jockers, R. (2020) · The FASEB Journal · doi:10.1096/fj.202000305r · Cited by 35
Quednow, B. B., Geyer, M. A., & Halberstadt, A. L. (2020) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-444-64125-0.00039-6 · Cited by 41
Long-lasting alterations in 5-HT2A receptor after a binge regimen of methamphetamine in mice
Chiu, H., Chan, M., Lee, M.-Y., Chen, S., Zhan, Z.-Y., & Chen, H. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000455 · Cited by 35
“Recently, down-regulation of mGlu2 receptors together with up-regulation of 5-HT2A receptors has been proposed as a pattern that could predispose to psychosis (Gonzalez-Maeso et al., 2008).”
BackgroundMetabotropic Glutamate 2/3 Receptors and Epigenetic Modifications in Psychotic Disorders: A Review
Matrisciano, F., Panaccione, I., Grayson, D. R., Nicoletti, F., & Guidotti, A. (2016) · Current Neuropharmacology · doi:10.2174/1570159x13666150713174242 · Cited by 31
“The finding that expression of mGlu2 receptors is reduced, and expression of 5-HT2A receptors is increased, in post-mortem cortical tissue of patients affected by SZ [61] suggests that an imbalance between mGlu2 and 5-HT2A receptors contributes to the pathophysiology of SZ and can be targeted by therapeutic interventi…”
BackgroundEbselen has lithium‐like effects on central 5‐HT2A receptor function
Antoniadou, I., Kouskou, M., Arsiwala, T., Singh, N., Vasudevan, S. R., Fowler, T. G., Cadirci, E., Churchill, G. C., & Sharp, T. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14179 · Cited by 35
“For instance, it is well known that 5-HT2A receptors are under the negative influence of mGlu2 receptors (González-Maeso et al., 2008).”
BackgroundFamily C G-Protein-Coupled Receptors in Alzheimer’s Disease and Therapeutic Implications
Prà, I. D., Armato, U., & Chiarini, A. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01282 · Cited by 33
On the fitting of binding data when receptor dimerization is suspected
Giraldo, J. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.234 · Cited by 31
“, 2008) or between 5-HT2A and metabotropic glutamate receptors (González-Maeso et al., 2008) becomes a challenge for further investigations on mechanistic modelling approaches.”
BackgroundUrigüen, L., Gil-Pisa, I., Munarriz‐Cuezva, E., Berrocoso, E., Pascau, J., Soto‐Montenegro, M. L., Gutiérrez‐Adán, A., Pintado, B., Madrigal, J. L. M., Castro, E., et al. (2013) · Translational Psychiatry · doi:10.1038/tp.2012.149 · Cited by 34
“of DOI (2,5-dimethoxy-4-iodoamphetamine) and, 5 min after injection, recorded for 10 min.(20) Subsequent head-twitch response (HTR) was scored.”
MethodSelf-citationG Protein-Coupled Receptor Heterocomplexes in Neuropsychiatric Disorders
Moreno, J. L., Holloway, T., & González-Maeso, J. (2013) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-386931-9.00008-8 · Cited by 30
Self-citationOverview of schizophrenia research and treatment in Pakistan
Nawaz, R., Gul, S., Amin, R., Huma, T., & Mughairbi, F. A. (2020) · Heliyon · doi:10.1016/j.heliyon.2020.e05545 · Cited by 36
“These combinations have proven very effective in the treatment of the positive, negative, and cognitive symptoms of SCZ [37, 38, 39, 40, 41].”
Background
Metadata
- Authors
- González-Maeso, J., Ang, R. L., Yuen, T., Chan, P., Weisstaub, N. V., López-Giménez, J. F., Zhou, M., Okawa, Y., Callado, L. F., Milligan, G., Gingrich, J. A., Filizola, M., Meana, J. J., & Sealfon, S. C.
- Affiliations
- University of the Basque Country (ES)
- University of Glasgow (GB)
- New York State Psychiatric Institute (US)
- Icahn School of Medicine at Mount Sinai (US)
- Corresponding author
- Sealfon, Stuart C.
- ORCID
- Venue
- Nature
- Published
- 2008-02-24
- Volume
- 452
- Issue
- 7183
- Pages
- 93-97
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC2743172
- OpenAlex
- W2024942419
- Cited by
- 803
- References
- 44
- Citations by year
- 2026: 18 · 2025: 21 · 2024: 23 · 2023: 34 · 2022: 44 · 2021: 38 · 2020: 36 · 2019: 33 · 2018: 45 · 2017: 44 · 2016: 51 · 2015: 37 · 2014: 52 · 2013: 62 · 2012: 71
- FWCI
- 27.83
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- Funders
- National Institute of Mental Health (U01MH083545)
- National Institute on Drug Abuse (T32DA007135, P01DA012923)
- National Institute of General Medical Sciences (T32GM062754)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- 5-HT2A receptor, mGluR2, metabotropic glutamate receptors, receptor complex, schizophrenia, psychosis, hallucinogens, LSD, psilocybin, cortical dysfunction, antipsychotic drug targets, postmortem brain
- MeSH terms
- Animals, Brain, Cell Line, Cells, Cultured, Hallucinogens, Humans, Models, Molecular, Protein Binding, Psychotic Disorders, Schizophrenia, Signal Transduction, Down-Regulation, Up-Regulation, Protein Structure, Tertiary, Receptors, Metabotropic Glutamate, Receptor, Serotonin, 5-HT2A, Multiprotein Complexes, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.